Last reviewed · How we verify
Meropenem Injection
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including intra-abdominal infections, Meningitis, Pneumonia.
At a glance
| Generic name | Meropenem Injection |
|---|---|
| Also known as | Tinidazole injection, meropenem,MEPEM, Supportive care as fluids and securing airway if needed, meroneum, penro |
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Drug class | Carbapenem antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall disruption and bacterial death. It has activity against a wide range of gram-positive and gram-negative bacteria, including anaerobes, making it effective for serious infections caused by susceptible organisms.
Approved indications
- Serious bacterial infections including intra-abdominal infections
- Meningitis
- Pneumonia
- Sepsis
- Febrile neutropenia
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Headache
- Phlebitis at injection site
- Seizures (in meningitis or renal impairment)
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency (PHASE1)
- Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever (PHASE4)
- Bolus Versus Continuous Infusion of Meropenem (PHASE4)
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections (PHASE3)
- Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (PHASE1)
- PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections (PHASE4)
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meropenem Injection CI brief — competitive landscape report
- Meropenem Injection updates RSS · CI watch RSS
- Institute of Liver and Biliary Sciences, India portfolio CI